Company Valuation: Mankind Pharma Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2024 2025 2026 2027
Capitalization 1 9,21,654 10,64,139 - -
Change - 15.46% - -
Enterprise Value (EV) 1 8,89,053 10,62,777 11,14,848 10,91,244
Change - 19.54% -1.46% -2.12%
P/E ratio 48.3x 49.3x 51x 39x
PBR 9.84x 6.98x 6.58x 5.71x
PEG 1x 15.46x 8x 1.3x
Capitalization / Revenue 8.92x 8.2x 7.18x 6.38x
EV / Revenue 8.6x 8.71x 7.52x 6.54x
EV / EBITDA 35.1x 35.2x 28.9x 24.2x
EV / EBIT 41.6x 44.3x 37x 30.2x
EV / FCF 48.4x 55.8x 43.6x 36.5x
FCF Yield 2.07% 1.79% 2.29% 2.74%
Dividend per Share 2 - 9 7.8 10.42
Rate of return - 0.35% 0.3% 0.4%
EPS 2 47.68 49.2 50.52 66.09
Distribution rate - 19% 15.4% 15.8%
Net sales 1 1,03,348 1,22,074 1,48,236 1,66,918
EBITDA 1 25,351 30,179 38,630 45,133
EBIT 1 21,368 23,967 30,139 36,172
Net income 1 19,129 19,910 20,959 27,142
Net Debt 1 -32,600 62,377 50,709 27,105
Reference price 2 2,300.75 2,578.30 2,578.30 2,578.30
Nbr of stocks (in thousands) 4,00,588 4,12,729 - -
Announcement Date 15/05/24 21/05/25 - -
1INR in Million2INR
Estimates

P/E ratio, Detailed evolution

P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
54.29x9.2x35.53x0.35% 1.24TCr
37.3x12.31x28.09x0.75% 71TCr
15.04x4.2x11.56x3.34% 38TCr
27.26x6.59x13.78x3.42% 34TCr
16.85x6.08x12.14x3% 31TCr
14.15x3.48x8.6x3.84% 26TCr
17.15x4.63x11.21x3.26% 24TCr
22.3x4.15x12.2x2.28% 22TCr
10.68x3.46x7.48x3.86% 21TCr
22.58x5.78x11.22x3.25% 16TCr
Average 23.76x 5.99x 15.18x 2.73% 28.29TCr
Weighted average by Cap. 23.23x 6.75x 15.58x 2.64%
See all sector valuations

Year-on-year evolution of the PER

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Equities
  3. MANKIND Stock
  4. Valuation Mankind Pharma Limited